Hyperpituitarism: Clinical Trials

6 terminated. 6 Phase 2.

By phase and status

Phase	Trials	Status
Phase 2	6	Terminated 6

Follow Hyperpituitarism: new trials by email Literature Review of Hyperpituitarism trials Research Report on Hyperpituitarism

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

Trial	Phase	Status	Sponsor	Enrollment	Start	Updated
ALXN2420 Versus Placebo in Combination With Somatostatin Analogs in Participants With Acromegaly ALXN2420, Placebo - Acromegaly	Phase 2	Terminated	Alexion Pharmaceuticals, Inc.	8	2025-10-28	2026-08-07
A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance) Paltusotine - Acromegaly	Phase 2	Terminated	Crinetics Pharmaceuticals Inc.	43	2020-01-29	2026-07-29
Assessment of BIM23B065, Given as Repeated Subcutaneous Injection in Subjects With Acromegaly BIM23B065 - Acromegaly	Phase 2	Terminated	Ipsen	4	2017-01-26	2019-03-08
Study of the Efficacy and Safety of Pasireotide s.c. +/- Cabergoline in Patients With Cushing's Disease Pasireotide with or without cabergoline - Cushings Disease	Phase 2	Terminated	Novartis Pharmaceuticals	68	2014-03-06	2020-09-18
Study to Assess the Efficacy and Safety of Repeated Administration of BIM 23A760 in Patients With Acromegaly BIM 23A760 - Acromegaly	Phase 2	Terminated	Ipsen	109	2009-10-01	2019-11-22
Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease) rosiglitazone maleate - Cushing's Disease	Phase 2	Terminated	Jonsson Comprehensive Cancer Center	2	2007-04-01	2020-08-06

Narrower conditions

Acromegaly (4)  ·  Pituitary ACTH Hypersecretion (2)  ·  Adrenocortical Hyperfunction (1)  ·  Pituitary Neoplasms (1)

Broader conditions

Brain Diseases (6)  ·  Central Nervous System Diseases (6)  ·  Endocrine System Diseases (6)  ·  Hypothalamic Diseases (6)  ·  Nervous System Diseases (6)  ·  Pituitary Diseases (6)  ·  Bone Diseases (4)  ·  Bone Diseases, Endocrine (4)  ·  Musculoskeletal Diseases (4)  ·  Adrenal Gland Diseases (1)  ·  Brain Neoplasms (1)  ·  Central Nervous System Neoplasms (1)  ·  Endocrine Gland Neoplasms (1)  ·  Hypothalamic Neoplasms (1)

Interventions

BIM23B065 (1)  ·  Cabergoline (1)  ·  Rosiglitazone (1)  ·  TBR-760 (1)  ·  pasireotide (1)

Sponsors

Ipsen (2)  ·  Alexion Pharmaceuticals, Inc. (1)  ·  Crinetics Pharmaceuticals Inc. (1)  ·  Jonsson Comprehensive Cancer Center (1)  ·  Novartis Pharmaceuticals (1)

Countries

United States (5)  ·  Belgium (3)  ·  Brazil (3)  ·  Hungary (3)  ·  France (2)  ·  Germany (2)  ·  Greece (2)  ·  Italy (2)  ·  Lithuania (2)  ·  Mexico (2)  ·  Netherlands (2)  ·  Romania (2)  ·  Serbia (2)  ·  Ukraine (2)  ·  Argentina (1)

Top investigators

Anthony Heaney, MD (1)

Results publications

PMID 37876540

NIH funding

2009 (1), 2015 (1), 2019 (1)